乙肝病毒感染与淋巴瘤化疗后肝损害关系初探
Study on the Relationship between Hepatitis Virus(HBV) and Liver Damage in Chemotherapy of Lymphoma
-
摘要: 目的: 探讨乙肝病毒感染与淋巴瘤化疗后肝损害关系。方法: 分析182例中高度恶性淋巴瘤化疗后肝功能改变, 其中携带乙肝病毒53例, 未携带者129例, 化疗前肝功能均正常, 观察化疗后肝功能变化情况。结果: 经过二周期以上的正规化疗后, HBsAg(+)组肝损害发生率占45.3 %(24/53), HBsAg(-)组肝损害发生率占27.1 %(35/129), P <0.05。HBsAg(+)组中并用利分能(重组人a-2b干扰素)治疗10例, 肝损害发生率为10.0 %(1/10), 而未用利分能治疗43例, 肝损害发生率为53.5 %(23/43), P <0.05。 结论: 乙肝病毒感染的淋巴瘤患者化疗后易致肝损害, 并用利分能治疗可减轻其损害。Abstract: Objective： Observing the ralationship between HBV and liver damage in chemotherapy of Lymphoma. Methods： Among 182 cases of lymphoma, 53 cases with positive serum HBV markerwhile 129 cases without HBV marker. The liver funtion of all cases were normal before chemotherapy, effort was made to observe the patients liver function damage after chemotherapy. Results： After two phasesregular chemotherapy, the liver damage was 45.3 % (24/53) in HBV(+) group and 27.1 % (35/129) in HBV(-)group (P <0.05). Furthermore, among the patients in HBV(+)group, 10 cases were treated with Interferon alfa -2b and the others didnt use the drug . Liver function damage was 10.0 %(1/10) in the former while 53.5 %(24/43) in the latter (P <0.05). Conclusion： The cases with HBV(+) were more likely to appear liver function damage, which could be alleviated by using Interferon alfa -2b.
下载:
